Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04456699
Registration number
NCT04456699
Ethics application status
Date submitted
1/07/2020
Date registered
2/07/2020
Date last updated
2/04/2024
Titles & IDs
Public title
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Query!
Scientific title
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)
Query!
Secondary ID [1]
0
0
MK-7339-003
Query!
Secondary ID [2]
0
0
7339-003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Colorectal Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Olaparib
Treatment: Drugs - 5-FU
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Capecitabine
Treatment: Drugs - Leucovorin/ levoleucovorin
Experimental: Olaparib + bevacizumab - Participants will receive olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study.
Experimental: Olaparib - Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
Active Comparator: Bevacizumab + chemotherapy - Participants will receive investigator's choice of either bevacizumab (7.5 mg/kg IV once every three weeks (Q3W)) + capecitabine (1000 mg/m^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5-FU (400 mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.
Treatment: Drugs: Olaparib
300 mg BID, oral until progressive disease or end of study
Treatment: Drugs: 5-FU
2400 mg/m^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
Treatment: Drugs: Bevacizumab
5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
Treatment: Drugs: Capecitabine
1000 mg/m^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
Treatment: Drugs: Leucovorin/ levoleucovorin
400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR).
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS using RECIST 1.1 as assessed by BICR is presented.
Query!
Timepoint [1]
0
0
Up to approximately 30 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to death due to any cause. The OS is presented.
Query!
Timepoint [1]
0
0
Up to approximately 30 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Query!
Assessment method [2]
0
0
ORR was defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR of all randomized participants who entered the with measurable disease is presented.
Query!
Timepoint [2]
0
0
Up to approximately 30 months
Query!
Secondary outcome [3]
0
0
Number of Participants With One or More Adverse Events (AE)
Query!
Assessment method [3]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE was reported for each arm.
Query!
Timepoint [3]
0
0
Up to approximately 30 months
Query!
Secondary outcome [4]
0
0
Number of Participants Discontinuing Study Intervention Due to an AE
Query!
Assessment method [4]
0
0
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE was reported for each arm.
Query!
Timepoint [4]
0
0
Up to approximately 30 months
Query!
Eligibility
Key inclusion criteria
1. Has a histologically-confirmed metastatic or unresectable (Stage IV as defined by
American Joint Committee on Cancer (AJCC eighth edition) colorectal adenocarcinoma
(National Comprehensive Cancer Network [NCCN] 2018).
2. Has not progressed (ie, achieved a stable disease [SD], partial response [PR], or
complete response [CR]) after a first-line induction course of at least 6 cycles of
FOLFOX + bevacizumab or 4 cycles of CAPOX + bevacizumab as first-line therapy.
- Participants must not have received an investigational agent during their
induction course.
- Determination of best overall response (SD/PR/CR) will be made by the
investigator.
- Non-PD will be verified by BICR prior to randomization based on the images
submitted to imaging contract research organization (iCRO) as described in
inclusion criterion 4.
- "First-line therapy" is defined as the first systemic chemotherapy regimen given
for the diagnosis of unresectable or metastatic CRC. Participants may have
received prior adjuvant/neoadjuvant chemotherapy for CRC, as long as it was
completed at least 6 months prior to initiation of first-line CAPOX + bevacizumab
or FOLFOX + bevacizumab induction treatment.
3. Has experienced unacceptable toxicity to oxaliplatin that, in the opinion of the
treating physician, requires/required the discontinuation of oxaliplatin. Note: As an
example, unacceptable toxicity may include (but is not limited to) severe or prolonged
neurotoxicity.
• Participants must be randomized within a minimum of 2 weeks and a maximum of 6 weeks
after their last dose of CAPOX + bevacizumab or FOLFOX + bevacizumab (last dose is the
day of the last infusion that contained oxaliplatin).
4. Has provided to the iCRO 1 set of baseline radiographic images taken before or during
the CAPOX + bevacizumab or FOLFOX + bevacizumab induction period and at least 42 days
prior to the imaging performed during Screening. Tumor imaging at Screening must be
performed within 28 days prior to the date of randomization.
5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within
10 days prior to randomization.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Has known hypersensitivity to the components and/or excipients in bevacizumab, 5-FU,
capecitabine, or olaparib.
2. Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Participants with previously treated brain metastases may participate
provided they are radiologically stable (ie, without evidence of progression for at
least 28 days by repeat imaging (note that the repeat imaging should be performed
during study screening), clinically stable and without requirement of steroid
intervention for at least 14 days prior to first dose of study intervention.
3. Has an active infection requiring systemic therapy.
4. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is
required unless mandated by local health authority.
5. Has a known history of or is positive for hepatitis B surface antigen (HBsAg reactive)
or hepatitis C ribonucleic acid (HCV RNA [qualitative]) is detected). Note: No testing
for hepatitis B and hepatitis C is required unless mandated by local health authority.
6. Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study.
7. Has myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or with features
suggestive of MDS/AML.
8. Has hemoptysis or hematemesis within 28 days prior to randomization.
9. Has evidence of bleeding diathesis or significant coagulopathy (in the absence of
anticoagulation).
10. Has clinically significant bleeding within 28 days prior to randomization.
11. Is considered a poor medical risk due to a serious, uncontrolled medical disorder,
nonmalignant systemic disease or active, uncontrolled infection. Examples include, but
are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months)
myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord
compression, superior vena cava syndrome, extensive interstitial bilateral lung
disease on high-resolution computed tomography (HRCT) scan or any psychiatric disorder
that prohibits obtaining informed consent.
12. Has 1 or more conditions that, in the opinion of the treating physician, make the
participant ineligible for treatment with bevacizumab. These conditions may include:
- Uncontrolled hypertension (systolic blood pressure [SBP] >150 mm Hg or diastolic
blood pressure [DBP] >100 mm Hg) or a history of hypertensive crisis or
hypertensive encephalopathy
- Arterial thromboembolic events (eg, myocardial infarction, cerebral infarction)
- History of nephrotic syndrome or moderate proteinuria
- History of gastrointestinal perforation
- History of non-gastrointestinal fistula formation
- History of possible reversible encephalopathy syndrome (RPLS)
13. Has received prior systemic anticancer therapy (other than CAPOX + bevacizumab or
FOLFOX + bevacizumab induction) including investigational agents within 28 days prior
to randomization. Note: Participants must have recovered from all AEs due to previous
therapies to =Grade 1 or baseline. Participants with persistent alopecia or Grade =3
neuropathy are eligible.
14. Has received prior therapy with olaparib or with any other polyadenosine
5'-diphosphoribose polymerase (PARP) inhibitor.
15. Is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin,
protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir,
nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin, erythromycin,
diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 3A4 (CYP3A4) that
cannot be discontinued for the duration of the study. The required washout period
prior to randomization is 2 weeks.
16. Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin,
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or
moderate (eg. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be
discontinued for the duration of the study. The required washout period prior to
randomization is 5 weeks for phenobarbital and 3 weeks for other agents.
17. Has undergone major surgery within 2 weeks of randomization or has not recovered
adequately from toxicities and/or complications from any major surgery prior to
randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/08/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/11/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
335
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
St George Hospital ( Site 0052) - Kogarah
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital ( Site 0055) - Liverpool
Query!
Recruitment hospital [3]
0
0
Royal Brisbane and Women s Hospital ( Site 0054) - Herston
Query!
Recruitment hospital [4]
0
0
Queen Elizabeth Hospital ( Site 0053) - Woodville South
Query!
Recruitment hospital [5]
0
0
Monash Health ( Site 0050) - Clayton
Query!
Recruitment hospital [6]
0
0
Peninsula Health Frankston Hospital ( Site 0056) - Frankston
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
0
0
3199 - Frankston
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maine
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Montana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Antwerpen
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles-Capitale, Region De
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Oost-Vlaanderen
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Vlaams-Brabant
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
West-Vlaanderen
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
New Brunswick
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Chile
Query!
State/province [26]
0
0
Araucania
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Region M. De Santiago
Query!
Country [28]
0
0
Colombia
Query!
State/province [28]
0
0
Cesar
Query!
Country [29]
0
0
Colombia
Query!
State/province [29]
0
0
Cordoba
Query!
Country [30]
0
0
Colombia
Query!
State/province [30]
0
0
Distrito Capital De Bogota
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Risaralda
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Santander
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Valle Del Cauca
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Bas-Rhin
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Bretagne
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Doubs
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Gironde
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Herault
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rhone-Alpes
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Paris
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Baden-Wurttemberg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Nordrhein-Westfalen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hamburg
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Bekes
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Borsod-Abauj-Zemplen
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Hajdu-Bihar
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Jasz-Nagykun-Szolnok
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Zala
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Budapest
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Aichi
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Chiba
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Ehime
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Kanagawa
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Saitama
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Shizuoka
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Fukuoka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Tokyo
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Taegu-Kwangyokshi
Query!
Country [61]
0
0
Latvia
Query!
State/province [61]
0
0
Daugavpils
Query!
Country [62]
0
0
Latvia
Query!
State/province [62]
0
0
Riga
Query!
Country [63]
0
0
Lithuania
Query!
State/province [63]
0
0
Kaunas
Query!
Country [64]
0
0
Lithuania
Query!
State/province [64]
0
0
Vilnius
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Arkhangel Skaya Oblast
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Baskortostan, Respublika
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Krasnoyarskiy Kray
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Moskovskaya Oblast
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Moskva
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Sankt-Peterburg
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Gauteng
Query!
Country [72]
0
0
South Africa
Query!
State/province [72]
0
0
Limpopo
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Western Cape
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Alicante
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Asturias
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Barcelona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Madrid
Query!
Country [78]
0
0
Turkey
Query!
State/province [78]
0
0
Adana
Query!
Country [79]
0
0
Turkey
Query!
State/province [79]
0
0
Ankara
Query!
Country [80]
0
0
Turkey
Query!
State/province [80]
0
0
Edirne
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Istanbul
Query!
Country [82]
0
0
Turkey
Query!
State/province [82]
0
0
Izmir
Query!
Country [83]
0
0
Turkey
Query!
State/province [83]
0
0
Konya
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Dnipropetrovska Oblast
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Kharkivska Oblast
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Kyivska Oblast
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Zaporizka Oblast
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Kyiv
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an efficacy and safety study of olaparib alone or in combination with bevacizumab
being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or
metastatic colorectal cancer who have not progressed following first-line induction. The
primary hypotheses are: Olaparib + Bevacizumab is superior to a fluoropyrimidine +
Bevacizumab with respect to progression-free survival (PFS) using Response Evaluation
Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central
review (BICR); Olaparib is superior to a fluoropyrimidine + Bevacizumab with respect to PFS
using RECIST 1.1 as assessed by BICR. As of amendment 5 study enrollment is being
discontinued and study participants randomized to one of the two experimental arms (olaparib
plus bevacizumab or olaparib monotherapy) must discontinue study intervention. Participants
who are still on study treatment will no longer have tumor response assessments by BICR.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04456699
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04456699
Download to PDF